JP5832541B2 - Ｋｒａｓ遺伝子変異型の結腸直腸癌患者に対する抗腫瘍剤及び治療効果予測方法 - Google Patents

Ｋｒａｓ遺伝子変異型の結腸直腸癌患者に対する抗腫瘍剤及び治療効果予測方法 Download PDF

Info

Publication number
JP5832541B2
JP5832541B2 JP2013529023A JP2013529023A JP5832541B2 JP 5832541 B2 JP5832541 B2 JP 5832541B2 JP 2013529023 A JP2013529023 A JP 2013529023A JP 2013529023 A JP2013529023 A JP 2013529023A JP 5832541 B2 JP5832541 B2 JP 5832541B2
Authority
JP
Japan
Prior art keywords
colorectal cancer
kras gene
chemotherapy
therapeutic effect
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013529023A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2013024865A1 (ja
Inventor
雅信 伊藤
雅信 伊藤
博之 岡部
博之 岡部
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Priority to JP2013529023A priority Critical patent/JP5832541B2/ja
Publication of JPWO2013024865A1 publication Critical patent/JPWO2013024865A1/ja
Application granted granted Critical
Publication of JP5832541B2 publication Critical patent/JP5832541B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
JP2013529023A 2011-08-16 2012-08-15 Ｋｒａｓ遺伝子変異型の結腸直腸癌患者に対する抗腫瘍剤及び治療効果予測方法 Active JP5832541B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013529023A JP5832541B2 (ja) 2011-08-16 2012-08-15 Ｋｒａｓ遺伝子変異型の結腸直腸癌患者に対する抗腫瘍剤及び治療効果予測方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2011177838 2011-08-16
JP2011177838 2011-08-16
JP2013529023A JP5832541B2 (ja) 2011-08-16 2012-08-15 Ｋｒａｓ遺伝子変異型の結腸直腸癌患者に対する抗腫瘍剤及び治療効果予測方法
PCT/JP2012/070745 WO2013024865A1 (ja) 2011-08-16 2012-08-15 Ｋｒａｓ遺伝子変異型の結腸直腸癌患者に対する抗腫瘍剤及び治療効果予測方法

Publications (2)

Publication Number Publication Date
JPWO2013024865A1 JPWO2013024865A1 (ja) 2015-03-05
JP5832541B2 true JP5832541B2 (ja) 2015-12-16

Family

ID=47715182

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013529023A Active JP5832541B2 (ja) 2011-08-16 2012-08-15 Ｋｒａｓ遺伝子変異型の結腸直腸癌患者に対する抗腫瘍剤及び治療効果予測方法

Country Status (21)

Country Link
US (1) US9371380B2 (enExample)
EP (1) EP2746404B1 (enExample)
JP (1) JP5832541B2 (enExample)
KR (1) KR101693090B1 (enExample)
CN (1) CN103764847B (enExample)
AU (1) AU2012295841B2 (enExample)
CY (1) CY1119869T1 (enExample)
DK (1) DK2746404T3 (enExample)
ES (1) ES2659264T3 (enExample)
HR (1) HRP20180130T1 (enExample)
HU (1) HUE035347T2 (enExample)
LT (1) LT2746404T (enExample)
NO (1) NO2746404T3 (enExample)
PL (1) PL2746404T3 (enExample)
PT (1) PT2746404T (enExample)
RS (1) RS56911B1 (enExample)
RU (1) RU2585528C2 (enExample)
SI (1) SI2746404T1 (enExample)
SM (1) SMT201800108T1 (enExample)
TW (1) TWI550089B (enExample)
WO (1) WO2013024865A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2998742A4 (en) * 2013-05-17 2017-01-18 Taiho Pharmaceutical Co., Ltd. Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
UA123403C2 (uk) * 2016-02-05 2021-03-31 Тайхо Фармасьютікал Ко., Лтд. Спосіб лікування хворих на рак з тяжкою нирковою недостатністю
AU2017397458B2 (en) * 2017-02-01 2025-07-10 Modernatx, Inc. RNA cancer vaccines
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1849470T5 (pl) 2005-01-26 2024-06-10 Taiho Pharmaceutical Co., Ltd. Lek przeciwrakowy zawierający alfa,alfa,alfa-trifluorotymidynę i inhibitor fosforylazy tymidynowej
US7799783B2 (en) 2005-01-26 2010-09-21 Taiho Pharmaceutical Co., Ltd. Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor

Also Published As

Publication number Publication date
JPWO2013024865A1 (ja) 2015-03-05
ES2659264T3 (es) 2018-03-14
NO2746404T3 (enExample) 2018-05-05
TW201319257A (zh) 2013-05-16
WO2013024865A1 (ja) 2013-02-21
RU2585528C2 (ru) 2016-05-27
TWI550089B (zh) 2016-09-21
EP2746404B1 (en) 2017-12-06
EP2746404A1 (en) 2014-06-25
SMT201800108T1 (it) 2018-05-02
RU2014109999A (ru) 2015-10-10
SI2746404T1 (en) 2018-04-30
DK2746404T3 (en) 2018-01-15
CY1119869T1 (el) 2018-06-27
HK1197086A1 (zh) 2015-01-02
HRP20180130T1 (hr) 2018-04-06
CN103764847B (zh) 2016-05-11
HUE035347T2 (en) 2018-05-02
PT2746404T (pt) 2018-01-10
PL2746404T3 (pl) 2018-04-30
CN103764847A (zh) 2014-04-30
KR20140057328A (ko) 2014-05-12
AU2012295841B2 (en) 2015-12-10
RS56911B1 (sr) 2018-05-31
EP2746404A4 (en) 2015-04-08
US9371380B2 (en) 2016-06-21
AU2012295841A1 (en) 2014-04-03
LT2746404T (lt) 2018-04-25
US20140213602A1 (en) 2014-07-31
KR101693090B1 (ko) 2017-01-04

Similar Documents

Publication Publication Date Title
JP7265985B2 (ja) Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物
AU2021327130A1 (en) Bicycle conjugates specific for Nectin-4 and uses thereof
JP5832541B2 (ja) Ｋｒａｓ遺伝子変異型の結腸直腸癌患者に対する抗腫瘍剤及び治療効果予測方法
TW202138566A (zh) 透過循環腫瘤dna分析之分子疾病評估之方法及系統
US20220396839A1 (en) Methods of detecting a fusion gene encoding a neoantigen
WO2022087018A1 (en) Improved fluorouracil-based multi-agent chemotherapy for treatment of metastatic colorectal cancer
HK1197086B (en) Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer
US20130005747A1 (en) Method for selecting a cancer therapy
JP5566376B2 (ja) 腎細胞癌に対する化学療法の治療効果予測方法
Duffy et al. Kinase Inhibition for Immuno-oncology
WO2025090966A1 (en) Mek inhibitors, alone or in combination with cdk4/5 inhibitors, for use in treating cancer
JPWO2010074240A1 (ja) 化学療法の治療効果予測方法
WO2025075211A1 (en) Alisertib and paclitaxel for treating small cell lung cancer
Searle et al. 104th Annual Meeting of the American Association for Cancer Research (AACR), Washington, DC, USA-March 6-10, 2013
JPWO2010134588A1 (ja) ジヒドロピリミジン脱水素酵素遺伝子の発現量を指標とした化学療法の治療効果予測方法
WO2010074241A1 (ja) 併用化学療法の治療効果予測方法
Dantas-Barbosa et al. 248 ORAL Notch pathway: a potential new target for the treatment of paediatric ependymomas

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150908

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151027

R150 Certificate of patent or registration of utility model

Ref document number: 5832541

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250